4/17/2012

Vanda Pharmaceuticals secured exclusive rights to develop Eli Lilly and Co.'s experimental drug VLY-686, which has shown potential to treat alcohol addiction. Lilly will receive $1 million upfront and as much as $99 million in milestone payments, plus sales royalties.

Related Summaries